NCT04773522View on ClinicalTrials.gov

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

October 14, 2022

Study Completion Date

September 4, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Talquetamab

Talquetamab will be administered subcutaneously.

Trial Locations (6)

247-8533

Shonan Kamakura General Hospital, Kamakura-shi

277 8577

National Cancer Center Hospital East, Kashiwa

467 8602

Nagoya City University Hospital, Nagoya

701-1192

National Hospital Organization Okayama Medical Center, Okayama

150-8935

Japanese Red Cross Medical Center, Shibuya City

028-3695

Iwate Medical University Hospital, Shiwa-gun

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT04773522 - A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter